Glioblastoma imaging for the detection of tumor progression using amide proton transfer weighted chemical exchange saturation transfer MRI

Glioblastoma imaging for the detection of tumor progression using amide proton transfer weighted chemical exchange saturation transfer MRI - GLIMPCE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57140

Enrollment

120

Registered

2024-10-23

Start date

2025-02-26

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain tumor glioblastoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of glioblastoma based on histopathological or molecular analysis of biopsy after surgery, or suspected of glioblastoma based on medical imaging. • Scheduled to undergo radiotherapy or combined chemo-and radiotherapy • 18 years and older • Able to give informed consent. • Patient will undergo clinically indicated MRIs

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded participation in this study: • Inability to give informed consent • Contraindication for MRI • Brain pathology affecting CEST contrast, such as a recent stroke or previous skull radiotherapy, as determined by the principal investigators (PIs)

Design outcomes

Primary

Measure	Time frame
Threshold on APTw-CEST images that accurately distinguishes between true progression and pseudoprogression in recently treated glioblastoma patients. The accuracy will be optimized using Receiver operating characteristic (ROC) curve analysis and the Youden index.	—

Countries

Netherlands

Outcome results